Appia Bio
Appia Bio, founded in 2020, is a biotechnology company based in Culver City, California, focused on developing allogeneic cell therapies for cancer and autoimmune diseases using its proprietary ACUA cellular technology platform.
Founded in 2020
Appia Bio was established in the year 2020 to pioneer advancements in the realm of allogeneic cell therapies aimed at cancer treatment. The company was created with the vision of developing innovative and efficacious therapeutic solutions for cancer patients.
Headquartered in Culver City, California
Appia Bio operates from its headquarters located in Culver City, California. This strategic location places the company within a hub of biomedical innovation and research.
ACUA Cellular Technology Platform
Appia Bio has developed the ACUA cellular technology platform, a proprietary system designed to create novel, curative, and accessible cell therapies. This platform is focused on producing scalable, universal off-the-shelf therapies aimed at providing broad access to cutting-edge treatments.
Therapies Targeting CAR-NKT and CAR-γδ T
The company's therapeutic pipeline includes promising treatments targeted at CAR-NKT for solid tumors and multiple myeloma, as well as CAR-γδ T cell therapies aimed at combating autoimmune diseases. These therapies leverage the potency and universality of invariant T cells to develop effective cancer treatments.
Focus on Invariant T Cells
Appia Bio's research and development efforts concentrate on harnessing the power of invariant T cells. These cells play a crucial role in the company's strategy to create potent, universal, and accessible treatments for cancer patients, reflecting their commitment to advancing the field of oncology.